Shire, Acceleron to Collaborate on Treatments for Rare Muscle Diseases
Shire Pharmaceuticals has signed a $498 million collaboration agreement with Acceleron Pharma to develop and commercialize treatments for muscular and neuromuscular disorders.
Shire Pharmaceuticals has signed a $498 million collaboration agreement with Acceleron Pharma to develop and commercialize treatments for muscular and neuromuscular disorders.
Americans are willing to use mobile devices to let physicians track their health, according to a new report from PricewaterhouseCoopers.
Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.
Operating for over 50 years, Safeguard Scientifics is a holding company that provides capital, as well as strategic, operational and management resources for technology and life sciences companies.
According to a recent Reuters article, a treatment known as therapeutic hypothermia is saving the lives of cardiac arrest patients in hospitals across the U.S.
Telcare, a Bethesda, Md.-based company focused on connecting patients with their doctors via wireless technology, has developed a wireless glucose meter that enables two-way communication between patient and caregiver.
Approximately 250,000 new diagnoses of MR are made each year, but only about 50,000 patients undergo surgery to fix the problem.
A recent study commissioned by the Society of Actuaries and completed by Milliman, Inc., highlighted both the high personal and financial costs exacted by measurable medical errors.
Copyright © 2024 | WordPress Theme by MH Themes